LOW-DOSE METFORMIN IN THE TREATMENT OF TYPE-II NON-INSULIN-DEPENDENT DIABETES - CLINICAL AND METABOLIC EVALUATIONS

被引:27
作者
GREGORIO, F
AMBROSI, F
MARCHETTI, P
CRISTALLINI, S
NAVALESI, R
BRUNETTI, P
FILIPPONI, P
机构
[1] UNIV PERUGIA,IST CLIN MED 1,CATTEDRA MALATTIE RICAMBIO,I-06100 PERUGIA,ITALY
[2] UNIV PISA,IST CLIN MED 2,CATTEDRA MALATTIE RICAMBIOL,I-56100 PISA,ITALY
[3] UNIV PERUGIA,IST PATOL SPECIALE MED,I-06100 PERUGIA,ITALY
来源
ACTA DIABETOLOGICA LATINA | 1990年 / 27卷 / 02期
关键词
Glycemic control; Insulin receptors; Intermediate metabolites; Metformin;
D O I
10.1007/BF02581286
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Low doses of metformin (500 mg twice daily) were administered to 20 diabetic patients, combined with the original sulfonylurea treatment which had become ineffective even at full dosage. After 1 and 5 weeks, the effects of the drug on glycemic control, blood intermediate metabolites and monocyte insulin receptors were monitored. Metformin clearly improved glycemic control by reducing both fasting blood glucose from 189.88±21.11 mg/dl to 131.12±16.02 mg/dl after 1 week and to 130.11±13.29 mg/dl after 5 weeks (p<0.025 both after 1 and 5 weeks); the diurnal blood glucose average fell from 235.33±24.11 mg/dl to 174.66±23.45 mg/dl (p<0.0025) after 1 week and to 177.65±21.71 mg/dl (p<0.0005) after 5 weeks. Consequently both blood glycosylated hemoglobin (p=n.s. after 1 week, p<0.025 after 5 weeks) and serum fructosamine (p<0.0025 after both 1 and 5 weeks) also decreased after metformin treatment. No change in plasma insulin and C-peptide levels was reported and no modification in diurnal rhythms of blood lactate, pyruvate, alanine glycerol and β-OH-butyrate was detected at any time during metformin treatment. All the changes documented in the binding values were already complete at the end of the first week: insulin binding to monocytes increased slightly but significantly (p<0.05) and the number of receptors per cell rose (p<0.05) but could not be correlated to any index of glycemic control. These data suggest that the antidiabetic action of metformin is neither related to its lactate-increasing activity nor does it depend upon its inducing an increase in insulin binding values. This metformin-related hypoglycemic effect might be the result, at least in part, of a reduced oxidative phosphorylation without inhibition of hepatic guconeogenesis and/or of decreased hepatic glucose output. Moreover, our data are also consistent with the hypothesis that metformin might affect insulin action at a post-receptor level. © 1990 Casa Editrica «il Ponte».
引用
收藏
页码:139 / 155
页数:17
相关论文
共 41 条
[1]  
ALENGRIN F, 1987, DIABETES METAB, V13, P591
[2]   CLINICAL USEFULNESS OF ESTIMATION OF SERUM FRUCTOSAMINE CONCENTRATION AS A SCREENING-TEST FOR DIABETES-MELLITUS [J].
BAKER, JR ;
OCONNOR, JP ;
METCALF, PA ;
LAWSON, MR ;
JOHNSON, RN .
BRITISH MEDICAL JOURNAL, 1983, 287 (6396) :863-867
[3]   DETERMINATION OF METFORMIN AND PHENFORMIN IN HUMAN-PLASMA AND URINE BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
BENZI, L ;
MARCHETTI, P ;
CECCHETTI, P ;
NAVALESI, R .
JOURNAL OF CHROMATOGRAPHY, 1986, 375 (01) :184-189
[4]  
BOYUM A, 1971, SCAND J CLIN INVEST, V55, P283
[5]  
CIGOLINI M, 1987, DIABETES METAB, V13, P20
[6]  
CIGOLINI M, 1984, DIABETES METAB, V10, P311
[7]   LACTIC-ACIDOSIS - SOME PHYSIOLOGICAL AND CLINICAL CONSIDERATIONS [J].
COHEN, RD ;
ILES, RA .
CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1977, 53 (05) :405-410
[8]  
DEMEYTS P, 1976, J BIOL CHEM, V251, P1877
[9]  
DESILVA SR, 1979, DIABETES METAB, V5, P223
[10]   CHARACTERIZATION OF 7 C-PEPTIDE ANTISERA [J].
FABER, OK ;
BINDER, C ;
MARKUSSEN, J ;
HEDING, LG ;
NAITHANI, VK ;
KUZUYA, H ;
BLIX, P ;
HORWITZ, DL ;
RUBENSTEIN, AH .
DIABETES, 1978, 27 :170-177